Results 41 to 50 of about 27,161 (265)

Pharmacokinetics, effectiveness and safety of certolizumab pegol in children and adolescents with active juvenile idiopathic arthritis: 9+‐year results from a multicenter, open‐label study

Arthritis &Rheumatology, Accepted Article.
Objective To assess the pharmacokinetics, effectiveness, safety, and immunogenicity of certolizumab pegol (CZP) in polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods Pediatric Arthritis Study of Certolizumab Pegol (NCT01550003), a multicenter, open‐label study, enrolled patients 2–17 years with active pcJIA and inadequate response ...
Hermine I Brunner, Lyudmila Grebenkina, Irina Nikishina, Ekaterina Alexeeva, Vyacheslav Chasnyk, Carlos Abud‐Mendoza, Nadina Rubio‐Pérez, Heinrike Schmeling, María del Rocio Maldonado‐Velázquez, Diane Brown, Andrew Zeft, Esi Morgan, C. Egla Rabinovich, Daniel Kingsbury, Hulya Bukulmez, Beth Gottlieb, Thomas Griffin, Lisa Imundo, Stacey Tarvin, Earl Silverman, Laura Shaughnessy, Saori Shimizu, Paulette Williams, Rocío Lledó‐García, Gauri Utturkar, Baran Ufuktepe, Alberto Martini, Daniel Lovell, Nicolino Ruperto   +28 more
wiley   +1 more source

Real-world pharmacovigilance study of drug-induced diabetes insipidus from the FAERS database

Endocrine Connections
Objective: This study aims to identify potential drugs associated with diabetes insipidus (DI) and track its epidemiological characteristics using the FDA Adverse Event Reporting System (FAERS) database.
Hui Lv, Yue Wu, Lan Lan, Nonger Shen
doaj   +1 more source

Preparation for the Inspection of the Pharmacovigilance System

Безопасность и риск фармакотерапии, 2021
The processes of planning, performing, documenting, and follow-up of pharmacovigilance system inspections are regulated by the Good Pharmacovigilance Practices (GVP) and local regulations.
B. K. Romanov
doaj   +1 more source

Adverse events of ursodeoxycholic acid: a real-world pharmacovigilance study using FAERS (2004–2023)

Frontiers in Medicine
BackgroundUrsodeoxycholic acid (UDCA) has been widely used in the treatment of hepatobiliary disorders and its clinical application is more and more extensive.
Yahui Ni, Xin Guan, Xiaoxue Gao, Ya Wang, Dongyuan Qin, Zhangtao Shan, Na Wang   +6 more
doaj   +1 more source

Knowledge, attitude and practice towards pharmacovigilance and reporting of adverse drug reactions among health care professionals in Albania: A cross-sectional study

Pakistan Journal of Pharmaceutical Sciences, 2023
In both developed and developing nations, the rising prevalence of adverse drug reactions (ADRs) and underreporting of ADRs in pharmacovigilance centers have become major problems.
Rezarta Shkreli, Klodiola Dhamo, Entela Haloi, Afrim Tabaku   +3 more
doaj   +1 more source

A pharmacovigilance study of antihypertensive medicines at a South Delhi hospital

Indian Journal of Pharmaceutical Sciences, 2009
The aim of the present study was to monitor adverse drug reactions associated with antihypertensive drugs. The study was conducted in medicine out patient department of 150-bed Majeedia Hospital at Hamdard University Campus in New Delhi. The study was conducted by way of one to one patient interview by a registered pharmacist using a questionnaire ...
Hussain, A., Aqil, M., Alam, M. S., Khan, M. R., Kapur, P., Pillai, K. K.   +5 more
openaire   +3 more sources

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

British Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun, Jingrong Yang, Lei Wan, Xia Xu, Jing Wang   +4 more
wiley   +1 more source

Disproportionality analyses of acoltremon: a real-world safety assessment based on the the FDA adverse event reporting system database

Frontiers in Medicine
IntroductionAcoltremon is a first-in-class transient receptor potential melastatin 8 agonist approved for the treatment of the signs and symptoms of dry eye disease.
Xiao Hu, Cong Yu, Yaping Huang
doaj   +1 more source

Strengthening adverse drug reaction reporting in Nepal

Asian Journal of Medical Sciences, 2015
Pharmacovigilance in Nepal is still in infancy. Till date only healthcare professionals are involved and the problem of underreporting is seen.
Nisha Jha
doaj   +1 more source

Comparative efficacy of GLP‐1 RA, tirzepatide and SGLT‐2 inhibitors in metabolic liver disease: A network meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aim Metabolic liver disease, including nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis, is a major cause of chronic liver dysfunction worldwide, creating an urgent need for effective treatments. This systematic literature review (SLR) and network meta‐analysis (NMA) systematically reviews and compares the efficacy and safety ...
Andrej Belančić, Christina Antza, Anastasios Poutachidis, Smaro Palaska, Elvira Meni Maria Gkrinia, Andrea Katrin Faour, Yusuf Ziya Sener, Seher Sener, Rehena Sultana   +8 more
wiley   +1 more source